

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**Guangzhou Innogen Pharmaceutical Group Co., Ltd.**

**廣州銀諾醫藥集團股份有限公司**

*(A joint stock company established in the People's Republic of China with limited liability)*

**(Stock Code: 2591)**

## **NOTICE OF BOARD MEETING**

The board (the “**Board**”) of directors (the “**Directors**”) of Guangzhou Innogen Pharmaceutical Group Co., Ltd. (the “**Company**”) hereby announces that a meeting of the Board will be held on Monday, 23 March 2026, for the purposes of, among other matters, considering and approving the annual results of the Company and its subsidiaries for the year ended 31 December 2025 and its publication.

By order of the Board  
**Guangzhou Innogen Pharmaceutical Group Co., Ltd.**  
**Dr. WANG QINGHUA**  
*Chairman of the Board*

Shanghai, the People's Republic of China, 10 March 2026

*As at the date of this announcement, the Board comprises Dr. WANG QINGHUA, Ms. Jiang Fan, Ms. Xu Wenjie and Mr. Huang Bing as executive Directors; Mr. HO KYUNG SHIK and Mr. Heng Lei as non-executive Directors; and Mr. Tao Wuping, Dr. Song Ruilin and Mr. Chan Heung Wing Anthony as independent non-executive Directors.*